Evidence suggests that glucagon-like peptide-1 (GLP-1) agonists are associated with reduced risk of CVS and renal events and sodium-glucose-cotransporter-2 (SGLT2) have improved renal outcomes in patients with T2DM. Here, GCG is linked to type 2 diabetes mellitus.